Management of Irritable Bowel Syndrome in Primary Care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS Trial) - Management of Irritable Bowel Syndrome in Primary Care: RCT (MIBS)

niversity of Southampton0 个研究点目标入组 150 人开始时间: 2009年10月23日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•Patients aged 16 to 60 yrs with symptoms of irritable bowel syndrome that fulfil the Rome III criteria.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Atypical symptoms – (unexplained weight loss, rectal bleeding), diagnosis of inflammatory bowel disease, coeliac disease, peptic ulcer disease, porphyria, pregnant or breast feeding, currently taking or allergy to mebeverine or methylcellulose. If patients are already taking mebeverine or methlycellulose but are keen to enter the trial they will be able to do so if they fulfil the inclusion criteria, do not meet any of the other exclusion criteria and they undertake a 4 week mebeverine and methylcellulose free wash out period before entering the trial.

发起方

niversity of Southampton